NDAORALSUSPENSION
Approved
Apr 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
4/8 — Partial
LIQREV (sildenafil citrate) by Viatris is pde-5 in the smooth muscle of the pulmonary vasculature, where pde-5 is responsible for degradation of cgmp. First approved in 2023.
Drug data last refreshed 3h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIQREV is an oral sildenafil citrate suspension approved in April 2023 for pulmonary arterial hypertension (PAH). It works by inhibiting phosphodiesterase-5 (PDE-5) in pulmonary vascular smooth muscle, increasing cGMP levels and promoting vasodilation of the pulmonary vascular bed. The drug offers approximately 4,000-fold selectivity for PDE-5 over PDE-3, minimizing cardiac contractility effects while maintaining therapeutic efficacy.
Peak12.3 years to LOE
Product is in peak commercial phase post-approval with Viatris backing; brand teams should expect ongoing market penetration and field force engagement in PAH specialty channels.
Mechanism of Action
PDE-5 in the smooth muscle of the pulmonary vasculature, where PDE-5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with PAH, this can lead to vasodilation of the pulmonary vascular bed…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form
Started Jan 2021
0Healthy
Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males
Started Jan 2014
30 enrolled
Healthy
Study of Sildenafil Citrate on Insulin Resistance in African American
Started Apr 2011
46 enrolled
Metabolic SyndromeObesity
A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate
Started Jan 2010
47 enrolled
Erectile Dysfunction
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
Started Sep 2004
76 enrolled
Pre-eclampsia
Worked on LIQREV at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.